Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegenerationNicholas J. Ashton, Henrik Zetterberg, Marc Suárez‐Calvet et al.|Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring|2021Cited by 128
Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkersSophia Weiner, Johan Gobom, Mathias Sauer et al.|Clinical Proteomics|2022Cited by 30
Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalusSophia Weiner, Johan Gobom, Antti Junkkari et al.|Fluids and Barriers of the CNS|2023Cited by 18
SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's diseaseSophia Weiner, Johan Gobom, Mathias Sauer et al.|Alzheimer s & Dementia|2023Cited by 9
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’Sophia Weiner, Johan Gobom, Mathias Sauer et al.|Molecular Neurodegeneration|2025Cited by 4